Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 7 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Sage Therapeutics LLC currently has 11 pending office actions within the Biotechnology & Pharmaceuticals technology area. These filings are spread across 7 distinct art units, reflecting a broad range of pharmaceutical research and development activity. This distribution across multiple art units suggests that the portfolio covers diverse chemical or biological innovations.
The prosecution of these matters involves 10 distinct examiners. Having this many examiners for 11 pending office actions means that almost every application is being reviewed by a different person, which may require the company to manage a wide variety of examination styles and preferences.
The busiest examiner for the company is LEE, WILLIAM Y, who is responsible for 2 pending office actions. While LEE, WILLIAM Y manages 2 pending office actions, the remainder of the portfolio is handled by examiners who each have only one case. This concentration of work with one examiner is minimal given the total number of pending matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (27%) |
| §112 only | 2 (18%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 2 | 48.0% | +34.1% |
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694572 | DEUTERATED POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719194 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | CHONG, YONG SOO | — |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | — |
| 18568624 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HAMA, JOANNE | — |
| 18263189 | USE OF NEUROACTIVE STEROIDS FOR TREATMENT OF SEXUAL DYSFUNCTION | BORALSKY, LUKE ALAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17579541 | FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | 124d overdue |
| 18201885 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | MOU, LIYUAN | 10d overdue |
| 18793028 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | FERGUSON, JALISA HOLMES | — |
| 18719194 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | CHONG, YONG SOO | — |
| 18636563 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | COUGHLIN, MATTHEW P | — |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | — |
| 18581595 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | LEE, WILLIAM Y | — |
| 18568624 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HAMA, JOANNE | — |
| Art Unit | Apps |
|---|---|
| 1623 | 3 |
| 1626 | 2 |
| 1625 | 2 |
| 1622 | 1 |
| 1647 | 1 |
| 1624 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18793028 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | FERGUSON, JALISA HOLMES | 1626 | DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18719194 | COMBINATION OF MUSCARINIC RECEPTOR POSITIVE MODULATORS AND NMDA POSITIVE ALLOSTERIC MODULATORS | CHONG, YONG SOO | 1623 | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18636563 | C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | COUGHLIN, MATTHEW P | 1626 | §112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18694572 | DEUTERATED POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18581595 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | LEE, WILLIAM Y | 1623 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18568624 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HAMA, JOANNE | 1647 | §102§103DP | Final Rejection | — | Pending | Dec 08, 2023 |
| 18263189 | USE OF NEUROACTIVE STEROIDS FOR TREATMENT OF SEXUAL DYSFUNCTION | BORALSKY, LUKE ALAN | 1624 | §102§103Other | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18201885 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | MOU, LIYUAN | 1628 | §103Other | Final Rejection | 10d overdue | Pending | May 25, 2023 |
| 17579541 | FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | 124d overdue | Pending | Jan 19, 2022 |
| 17251475 | A 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | LEE, WILLIAM Y | 1623 | §103DP | Final Rejection | — | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSage Therapeutics LLC has 11 pending office actions as of October 2026, spread across 7 art units and 10 examiners.
William Y Lee has the most, with 2 of Sage Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
